Literature DB >> 2590999

Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.

K W Rosbe1, T W Brann, S A Holden, B A Teicher, E Frei.   

Abstract

We examined the ability of lonidamine, which has been described as an inhibitor of cellular respiration and glycolysis, to enhance the cytotoxicity of alkylating agents to MCF-7 human breast-carcinoma cells. Lonidamine was increasingly cytotoxic to MCF-7 cells with increasing time of exposure. With a 12-h exposure, the IC50 for lonidamine was about 365 microM, and with a 24-h exposure it was about 170 microM. A drug concentration of 250 microM was chosen for use in the drug combination studies. Lonidamine appeared to have a dose-modifying effect on cisplatin (CDDP), producing increasingly supra-additive cell kill with increasing CDDP concentration. When simultaneously incubated with lonidamine for 1 h, 500 microM CDDP yielded a cell kill that was 2 log greater than additive cytotoxicity. Extending the exposure to lonidamine for 12 h after CDDP treatment led to a small, additional aliquot of cell kill of about 2.5-fold over the CDDP concentration range. Lonidamine also appeared to have a dose-modifying effect on melphalan cytotoxicity in the melphalan concentration range of 100-500 microM. Between concentrations of 10 and 100 microM melphalan, the drug combination survival after 1 h exposure fell within the envelope of additivity for the two agents. However, maintaining the presence of lonidamine for an additional 12 h increased the effect such that the combination was supra-additive over the entire concentration range of melphalan. Simultaneous exposure to 4-hydroperoxycyclophosphamide (4-HC) and lonidamine for 1 h resulted in greater than additive cell kill, and extending the lonidamine exposure period such that lonidamine was present during and 12 h after 4-HC treatment further increased this effect. Lonidamine had a moderate effect on the cytotoxicity of carmustine (BCNU) with a 1 h simultaneous exposure; however, this treatment combination reached greater than additive cytotoxicity only at the highest concentration of BCNU tested. Extending the lonidamine exposure time for an additional 12 h resulted in supra-additive cell kill over the BCNU concentration range. Therefore, when lonidamine was present during exposure to the alkylating agent and its presence was then extended for an additional 12 h, a synergistic cell kill was produced with all four alkylating agents tested.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2590999     DOI: 10.1007/bf00694335

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

1.  Phase II study of lonidamine in patients with small cell carcinoma of the lung.

Authors:  N Murray; A Shah; P Band
Journal:  Cancer Treat Rep       Date:  1987-12

2.  Radiosensitization with 5-bromodeoxyuridine of Chinese hamster cells x-irradiated during different phases of the cell cycle.

Authors:  W C Dewey; L E Stone; H H Miller; R E Giblak
Journal:  Radiat Res       Date:  1971-09       Impact factor: 2.841

3.  Lonidamine: a hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo.

Authors:  J H Kim; S H Kim; A Alfieri; C W Young; B Silvestrini
Journal:  Oncology       Date:  1984       Impact factor: 2.935

4.  Effects of Lonidamine on murine and human tumor cells in vitro. A morphological and biochemical study.

Authors:  C De Martino; T Battelli; M G Paggi; A Nista; M L Marcante; S D'Atri; W Malorni; M Gallo; A Floridi
Journal:  Oncology       Date:  1984       Impact factor: 2.935

5.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity.

Authors:  G G Steel; M J Peckham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-01       Impact factor: 7.038

6.  Phase II study of Lonidamine in cancer patients.

Authors:  P R Band; M Deschamps; J G Besner; R Leclaire; P Gervais; A De Sanctis
Journal:  Oncology       Date:  1984       Impact factor: 2.935

7.  Lonidamine and hyperthermia: clinical experience in melanoma. Preliminary results.

Authors:  R Cavaliere; F Di Filippo; A Varanese; S Carlini; A Calabro; L Aloe; L Piarulli
Journal:  Oncology       Date:  1984       Impact factor: 2.935

8.  Cell membrane changes induced by lonidamine in human erythrocytes and T lymphocytes, and Ehrlich ascites tumor cells.

Authors:  C De Martino; W Malorni; L Accinni; F Rosati; A Nista; G Formisano; B Silvestrini; G Arancia
Journal:  Exp Mol Pathol       Date:  1987-02       Impact factor: 3.362

9.  Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.

Authors:  A Floridi; M G Paggi; S D'Atri; C De Martino; M L Marcante; B Silvestrini; A Caputo
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

10.  Inhibition of the recovery from potentially lethal damage by lonidamine.

Authors:  G M Hahn; I van Kersen; B Silvestrini
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

View more
  14 in total

1.  Regulation of glycolysis in head and neck squamous cell carcinoma.

Authors:  Dhruv Kumar
Journal:  Postdoc J       Date:  2017-01

Review 2.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Authors:  Siver Andreas Moestue; Olav Engebraaten; Ingrid Susann Gribbestad
Journal:  Mol Oncol       Date:  2011-04-23       Impact factor: 6.603

Review 3.  Small mitochondria-targeting molecules as anti-cancer agents.

Authors:  Feng Wang; Marcia A Ogasawara; Peng Huang
Journal:  Mol Aspects Med       Date:  2009-12-06

4.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Targeting metabolic transformation for cancer therapy.

Authors:  Daniel A Tennant; Raúl V Durán; Eyal Gottlieb
Journal:  Nat Rev Cancer       Date:  2010-03-19       Impact factor: 60.716

Review 6.  Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets.

Authors:  Vlad C Sandulache; Jeffrey N Myers
Journal:  Head Neck       Date:  2011-02-14       Impact factor: 3.147

7.  Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.

Authors:  B A Teicher; T S Herman; J Tanaka; B Dezube; A Pardee; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.

Authors:  B A Teicher; S A Holden; V Khandakar; T S Herman
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.

Authors:  S Savini; W Zoli; O Nanni; A Volpi; G L Frassineti; E Magni; A Flamigni; A Amadori; D Amadori
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 10.  The Warburg effect and its cancer therapeutic implications.

Authors:  Zhao Chen; Weiqin Lu; Celia Garcia-Prieto; Peng Huang
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.